QMS Medical Allied Services Limited (NSE: QMSMEDI) announced on September 28th, 2026, its plan to acquire BeamOptics Scientific, a Pune-based diagnostics and analytical deep-tech company. This strategic move aims to bolster QMS’s product business, now the primary segment following the demerger of its services business into Saarathi Healthcare. The acquisition aligns with QMS’s strategy to expand its product portfolio in value-added segments.

Strategic Expansion

The acquisition of BeamOptics will be finalized subject to mutual fulfillment of terms and conditions and post NCLT approval of the composite scheme of arrangement with Health Care at Home (HCAH). Commenting on the acquisition, Mr. Mahesh Makhija, Chairman & Managing Director of QMS Medical Allied Services Limited, said, “I welcome the BeamOptics team to the QMS family and remain confident that the combined impact of niche technology, pan-India distribution, and brand reputation will lead to large-scale growth opportunities.”

Company Background

BeamOptics Scientific Private Limited, founded in 2023, is an ISO 13485/2016-certified, IP-led deep-tech company developing and manufacturing diagnostic devices and analytical instruments. Its products combine optical sensing, spectroscopy, Computer Vision, Acoustic Sensing, Multispectral Imaging, and Artificial Intelligence. BeamOptics has developed the FTIR (Fourier Transform Infrared) Interferometer and has built its own FTIR spectroscopy platform, filing several patents.

As part of its value-creation strategy, QMS has demerged its services business into its wholly-owned subsidiary, Saarathi Healthcare, and merged its Patient Services Program portfolio with Health Care at Home (HCAH). The product business will continue to operate under QMS Medical Allied Services. This acquisition is a natural extension of QMS’s value-unlocking and business leadership strategies, enabling its product and services portfolio offerings to evolve to the next stage of growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.

QMS Medical Allied Services Limited (NSE: QMSMEDI) announced a strategic partnership with Health Care At Home India Pvt Ltd (HCAH) to launch India’s largest patient support program. The merger of their pharma services businesses will create Saarathi Healthcare, a 100% subsidiary of QMS. This new platform will operate 160+ Patient Support Programs impacting over 1.2 million+ patients, supported by 2,000+ professionals across 35+ cities.

Strategic Merger

The partnership aims to combine complementary capabilities in patient screening, enrolment, therapy initiation, adherence, patient assistance, and disease management. Together, they will create a more comprehensive platform to support pharmaceutical companies and patients across the continuum of care.

Market Potential

The global patient support services market is estimated at c.US$70 billion, with India’s market growing at a CAGR of 15-20% to reach c.US$1 billion by 2030. This growth is driven by tighter promotional regulations, rising chronic disease prevalence, and greater focus on continuous patient monitoring and recovery.

Mahesh Makhija, Founder, Chairman & Managing Director of QMSMEDI, emphasized the value creation for shareholders and the enhanced support for patients throughout their treatment journey. Aditya Burman, Non-Executive Director of HCAH, highlighted the importance of patient support in the healthcare journey, particularly for chronic conditions requiring sustained engagement.

This initiative will fortify QMS’s role in the evolving healthcare ecosystem, leveraging healthcare expertise, digital capabilities, and scalable service models.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.

QMS Medical Allied Services Ltd (QMS MAS) has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary. This acquisition marks a significant step in QMS MAS’s strategy to build an integrated healthcare services platform. The company began its acquisition journey with Saarathi Healthcare in June 2024 with a 51% stake, which was subsequently increased to 76% in October 2025. With the acquisition of the remaining 24% stake, QMS MAS now holds 100% ownership of Saarathi Healthcare.

Strategic Expansion

The complete acquisition will significantly boost QMS MAS’s services portfolio and further strengthen its presence in the healthcare services and patient management segment. QMS MAS specializes in patient screening services through innovative Patient Service Programs (PSP) and the supply of diagnostic medical devices, enabling access to advanced diagnostic testing and supporting early intervention and preventive healthcare.

Enhanced Capabilities

Saarathi Healthcare brings complementary capabilities across disease management, early diagnosis, and screening through point-of-care devices, disease awareness, and access programs across therapies. Its model combines digital tools with physical patient engagement, enabling healthcare programs across different stages of the patient journey. This acquisition will allow QMS MAS to provide a more connected continuum of care.

Commenting on the acquisition, Mr. Mahesh Makhija, CMD, QMS Medical Allied Services Ltd, said, “The 100% acquisition of Saarathi Healthcare marks an important milestone in our journey towards building a comprehensive and integrated healthcare services platform. By bringing together QMS MAS’s strengths in patient screening and diagnostics with Saarathi’s capabilities in disease management and patient engagement, we aim to provide a more connected continuum of care. Full ownership will enable us to drive deeper integration, strengthen operational synergies, and create greater value for patients, healthcare partners, and stakeholders.”

As part of the transaction, QMS MAS acquired the balance 24% equity stake comprising 1,98,000 shares for a cash consideration of ₹14.225 crore, increasing its shareholding in Saarathi Healthcare from 76% to 100%. This development further strengthens QMS MAS’s broader strategy of building an integrated healthcare platform spanning early detection, patient screening, disease management, and sustained patient engagement.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.